바이오솔루션

086820KOSDAQ기초 의약물질 제조업

45.8 / 100

Reference Date: 2026-07-24

Financial Score10.0 / 40

News Sentiment19.8 / 25

Momentum6.0 / 20

Disclosure10.0 / 15

AI Analysis: PER raises overvaluation concerns, PBR raises overvaluation concerns. Roughly flat over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

BioSolution is a biotech company specializing in the research, development, and commercialization of advanced biopharmaceuticals, human tissue models, and biofusion materials based on stem cell and tissue engineering technologies. Key products include Kerahil for burn treatment and Catilife for cancer therapy, with OECD and ISO certifications enabling entry into alternative toxicity testing markets. The company also leads the clean and vegan cosmetics market through biofusion materials derived from plant stem cells and natural substances.

Number of Employees

100people

Average Salary

57.2M KRW

Score Calculation Basis

Detailed Financial Score

PER

547.27Industry Average 25.440.0Point

21.5x industry avg (risky)

PBR

4.88Industry Average 1.260.0Point

3.9x industry avg (risky)

ROE

0.86Industry Average -6.033.5Point

Well below industry avg

Debt Ratio

7.08Industry Average 6.622.0Point

Higher than industry avg (caution)

Trend 2023~20254.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲10.7% (2-year basis)

Operating Profit Growth Rate

2.0 / 3

Avg ▲6.8% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -11.5% (improving, 3yr)

Detailed News Sentiment

11 totalPositive 9Neutral 2Negative 0Average Sentiment Score 79.1

Neutral
바이오솔루션, 전 축구 국가대표 수비수 조성환 코치 공식 앰버서더 .....
바이오솔루션은 축구 코치 조성환을 앰버서더로 위촉하여 건강 캠페인을 시작했으나, 직접적인 재무 영향은 미미해 보입니다.
Positive
주사 1번으로 연골 보호·재생 노린다…바이오솔루션 '스페로큐어' 임.....
바이오솔루션의 새로운 세포치료제 '스페로큐어'가 골관절염 치료에 혁신적 접근을 제시하며 임상 시험 진입을 앞두고 있어 긍정적 전망.
Positive
[인터뷰] 이정선 바이오솔루션 대표 "스페로큐어 주사 DMOAD 승부"
바이오솔루션의 새로운 DMOAD 주사형 치료제 스페로큐어가 임상 시험에서 긍정적인 결과를 보여주며 회사의 미래 성장 가능성을 높임.

Detailed Momentum

52-week position1.0Point

Near 52w low (6%, downtrend)

Current 6,020Won52-week high 12,95052-week low 5,510

1-month return3.0Point

1m 0.33% (flat)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral투자판단관련주요경영사항(임상시험계획승인신청등결정) (동종 연골세포 스페로이드(스페로큐어)의 제1/2a상 임상시험계획 승인)2026-07-14